Completed Phase 1 AIDS-Related Complex trials

Showing 1 to 25 of 98. Each trial links to its page on Pharma Observatory.

• Study of Betalutin for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma (LYMRIT-37-05) NCT02658968·Phase 1·Completed·Nordic Nanovector·Started 2017
• A Phase I Trial of Intranasal Peptide T: Safety, Toxicity, and Pharmacokinetics in Human Immunodeficiency Virus-1 (HIV-1) Infected Patients. NCT00000391·Phase 1·Completed·National Institute of Mental Health (NIMH)·Started 1988
• A Pharmacokinetic Study of L-697,661 Alone and in Combination With Zidovudine NCT00000628·Phase 1·Completed·Merck Sharp & Dohme LLC
• A Phase I Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of Immuno-AG Recombinant HIV gp160 in Asymptomatic HIV Seropositive Individuals NCT00000633·Phase 1·Completed·National Institute of Allergy and Infectious Diseases (NIAID)
• A Phase I Study of the Safety and Pharmacokinetics of Recombinant CD4 Immunoglobulin G (rCD4-IgG) in HIV-1 Seropositive Women During the Last Trimester of Pregnancy and Their Newborns NCT00000642·Phase 1·Completed·National Institute of Allergy and Infectious Diseases (NIAID)
• A Phase I Dose Escalation Study of Synthetic Hypericin in HIV-Infected Patients With Less Than 300 CD4 Lymphocytes NCT00000645·Phase 1·Completed·National Institute of Allergy and Infectious Diseases (NIAID)
• An Open-Label, Staggered Rising Dose Cohort Study Assessing the Pharmacokinetics, Safety, and Tolerance of BI-RG-587 in Combination With Zidovudine in Patients With HIV Infection (CD4+ Cell Count < 400/mm3) NCT00000649·Phase 1·Completed·Boehringer Ingelheim
• A Phase I Safety and Pharmacokinetics Study of 2',3'-Dideoxyinosine (ddI) Administered Twice Daily to Infants and Children With AIDS or Symptomatic HIV Infection NCT00000669·Phase 1·Completed·National Institute of Allergy and Infectious Diseases (NIAID)
• A Phase I Study of the Safety and Pharmacokinetics of Recombinant Human CD4 Immunoglobulin (rCd4-IgG) Administered by Intravenous Bolus in Patients With AIDS and AIDS Related Complex NCT00000675·Phase 1·Completed·National Institute of Allergy and Infectious Diseases (NIAID)
• A Phase I Study of Autologous, Activated CD8(+) Lymphocytes Expanded In Vitro and Infused With or Without Recombinant Interleukin-2 to Patients With AIDS or Severe ARC NCT00000680·Phase 1·Completed·National Institute of Allergy and Infectious Diseases (NIAID)
• Phase I Rising Dose Tolerability Study of SC-48334 in Patients With Acquired Immunodeficiency Syndrome (AIDS) and Advanced AIDS Related Complex NCT00000692·Phase 1·Completed·G D Searle
• A Phase I/II Open Label Study To Evaluate the Antiviral Potential of Combination Low-Dose Therapy With Zidovudine and Interferon-Alpha 2A in Patients With Symptomatic HIV Disease NCT00000696·Phase 1·Completed·National Institute of Allergy and Infectious Diseases (NIAID)
• A Phase I/II Trial of Ribavirin (With Escalation) + Isoprinosine in Asymptomatic HIV-Viremic Patients NCT00000699·Phase 1·Completed·National Institute of Allergy and Infectious Diseases (NIAID)
• A Phase I Evaluation of Azidothymidine (AZT) in Children With Acquired Immune Deficiency Syndrome (AIDS) or AIDS Related Complex (ARC) NCT00000701·Phase 1·Completed·National Institute of Allergy and Infectious Diseases (NIAID)
• A Multicenter Dose Ranging Clinical Trial of 2',3'-Dideoxycytidine in the Treatment of Patients With AIDS and Advanced ARC. NCT00000704·Phase 1·Completed·National Institute of Allergy and Infectious Diseases (NIAID)
• A Phase I Safety, Efficacy, and Pharmacokinetic Study of 2',3'-Dideoxyinosine (ddI) Administered Twice Daily to Patients With AIDS or AIDS Related Complex NCT00000710·Phase 1·Completed·National Institute of Allergy and Infectious Diseases (NIAID)
• Granulocyte-Macrophage Colony-Stimulating Factor and Zidovudine: A Phase I Study of Concurrent Administration in Patients With AIDS and Severe ARC NCT00000711·Phase 1·Completed·National Institute of Allergy and Infectious Diseases (NIAID)
• A Phase I Clinical Trial To Evaluate the Toxicity, Antiviral and Immunomodulatory Effects of a Range of Doses of Ampligen in HIV-Infected Subjects NCT00000713·Phase 1·Completed·National Institute of Allergy and Infectious Diseases (NIAID)
• An Escalating Dose Tolerance Trial of BG8962 (rCD4) in Patients Who Are HIV Antibody Positive NCT00000721·Phase 1·Completed·National Institute of Allergy and Infectious Diseases (NIAID)
• Phase I Trial of the Combination of Zidovudine and Recombinant Interleukin-2 in Patients With Persistent Generalized Lymphadenopathy NCT00000728·Phase 1·Completed·National Institute of Allergy and Infectious Diseases (NIAID)
• A Multicenter Study To Determine Foscarnet Dose Response in HIV Infected Patients With PGL and/or Constitutional Disease NCT00000729·Phase 1·Completed·National Institute of Allergy and Infectious Diseases (NIAID)
• A Clinical Trial To Evaluate the Toxicity and Antiviral Effects of a Range of Doses of Ampligen in p24 Antigen Positive HIV-Infected Patients With AIDS or ARC NCT00000735·Phase 1·Completed·National Institute of Allergy and Infectious Diseases (NIAID)
• Randomized, Double-Blind, Placebo-Controlled Trial of Nimodipine for the Neurological Manifestations of HIV-1 NCT00000738·Phase 1·Completed·National Institute of Allergy and Infectious Diseases (NIAID)
• Comparison of Two Dosage Regimens of Oral Dapsone for Prophylaxis of Pneumocystis Carinii Pneumonia in Pediatric HIV Infection NCT00000739·Phase 1·Completed·National Institute of Allergy and Infectious Diseases (NIAID)
• Escalating Multiple-Dose Safety and Tolerance of WR 6026 Hydrochloride in HIV-Infected Subjects NCT00000740·Phase 1·Completed·National Institute of Allergy and Infectious Diseases (NIAID)